Advertisement
A vs ALC
Which Stock Would AI Choose? Agilent Technologies (A) vs. Alcon (ALC) Stock Comparison
Key Takeaways
- Agilent Technologies (A) focuses on analytical instruments and lab solutions across life sciences and diagnostics, while Alcon (ALC) specializes in ophthalmic surgical equipment and vision care products.
- Recent market activity shows Agilent (A) benefiting from broad segment growth and earnings beats in fiscal Q2 2026, with raised full-year expectations.
- Alcon (ALC) reported Q1 2026 revenue growth of approximately 10% driven by new product launches, despite a minor top-line miss that prompted initial share pressure.
- Both stocks operate in healthcare-adjacent sectors with exposure to innovation cycles, though Agilent (A) exhibits broader end-market diversification compared to Alcon’s (ALC) concentrated eye-care focus.
- Relative performance in recent weeks reflects differing earnings momentum, with Agilent (A) demonstrating more consistent positive revisions versus Alcon’s (ALC) mixed analyst reactions.
- Market sentiment remains tied to macroeconomic factors affecting capital spending and elective procedures for each company.
Introduction
Agilent Technologies (A) and Alcon (ALC) represent two distinct segments within the broader healthcare and life sciences ecosystem. Agilent (A) supplies precision instruments and services to laboratories worldwide, supporting research, diagnostics, and industrial applications. Alcon (ALC) develops and markets surgical devices and vision care solutions primarily for ophthalmic conditions. This comparison appeals to investors and traders seeking exposure to innovation-driven healthcare names with differing business models, growth drivers, and sensitivity to capital expenditure trends. The analysis highlights observable performance patterns, sector positioning, and recent developments to inform relative assessments in the current environment.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides instruments, software, services, and consumables for life sciences, diagnostics, and applied chemical markets. Its offerings support pharmaceutical research, environmental testing, food safety, and clinical diagnostics. In recent market activity, the stock has reflected strength following a fiscal second-quarter 2026 earnings beat, with revenue growth across end markets including pharmaceuticals and chemical analysis. Core revenue expanded notably, and management adjusted full-year guidance upward. Performance in recent weeks has been supported by sustained demand for laboratory solutions amid ongoing research and quality-control needs. Broader sentiment benefits from the company’s diversified customer base, which helps mitigate sector-specific volatility compared to more specialized peers.
Alcon (ALC) Overview and Recent Performance
Alcon (ALC) is a global leader in eye care, operating through Surgical and Vision Care segments that include intraocular lenses, surgical equipment, contact lenses, and related products. The company serves patients and professionals across more than 140 countries. Recent market activity shows Alcon (ALC) delivering approximately 10% sales growth in the first quarter of 2026, fueled by new product introductions and commercial execution. Despite an earnings-per-share beat, a slight revenue shortfall relative to expectations contributed to share volatility earlier in the period. Performance in recent weeks has been influenced by ongoing launches and analyst commentary on competitive positioning. The stock’s trajectory reflects both the stability of recurring vision-care demand and sensitivity to procedure volumes and innovation cycles.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a much larger library of hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters. Only those demonstrating strong suitability for prevailing market conditions—based on backtested statistics, consistency metrics, and adaptability—earn placement in the trending section. Available bots span a wide range of performance profiles, win rates, drawdown tolerances, and ticker universes, allowing users to explore options aligned with specific objectives. The platform emphasizes data-driven selection to highlight bots with favorable risk-reward characteristics in the current environment. Review the full selection of Trending AI Robots to identify candidates matching individual trading preferences.
Head-to-Head Comparison
Agilent Technologies (A) and Alcon (ALC) differ markedly in business models: Agilent (A) emphasizes capital equipment and recurring consumables for diverse laboratory applications, while Alcon (ALC) centers on medical devices and consumables tied to eye-health procedures and daily vision correction. Growth drivers for Agilent (A) include research-and-development spending and regulatory testing demand, whereas Alcon (ALC) benefits from aging demographics, refractive surgery trends, and new intraocular lens technologies. Recent momentum favors Agilent (A) following stronger earnings revisions, while Alcon (ALC) contends with more variable analyst sentiment. Risk factors for Agilent (A) include cyclical capital spending, while Alcon (ALC) faces reimbursement pressures and competitive intensity in surgical markets. Sector exposure places both in healthcare, yet Agilent (A) offers broader industrial diversification. Market sentiment reflects these contrasts, with Agilent (A) showing relatively steadier positioning in recent activity.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, guidance revisions, and relative stability in recent market activity, Tickeron’s AI models currently assign a modestly higher probabilistic preference to Agilent Technologies (A) over Alcon (ALC). Agilent’s (A) broader end-market exposure and recent positive momentum provide a more consistent trend profile, while Alcon (ALC) exhibits greater sensitivity to product-launch execution and procedure volumes. This assessment remains probabilistic and subject to evolving data; no definitive outcome is implied.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and ALC is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileALC’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- ALC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while ALC’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 4 bearish.
- ALC’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +5.05% price change this week, while ALC (@Pharmaceuticals: Other) price change was +4.27% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.31%. For the same industry, the average monthly price growth was +8.66%, and the average quarterly price growth was +24.82%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +6.33%. For the same industry, the average monthly price growth was +10.51%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
A is expected to report earnings on Aug 26, 2026.
ALC is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical Specialties (+1.31% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+6.33% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | ALC | A / ALC | |
| Capitalization | 41.9B | 35.3B | 119% |
| EBITDA | 1.96B | 2.54B | 77% |
| Gain YTD | 9.598 | -6.636 | -145% |
| P/E Ratio | 29.77 | 56.17 | 53% |
| Revenue | 7.23B | 10.6B | 68% |
| Total Cash | 1.81B | 1.66B | 109% |
| Total Debt | 3.36B | 5.25B | 64% |
A | ALC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 95 | 91 | |
SMR RATING 1..100 | 45 | 88 | |
PRICE GROWTH RATING 1..100 | 11 | 48 | |
P/E GROWTH RATING 1..100 | 47 | 17 | |
SEASONALITY SCORE 1..100 | 42 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is in the same range as ALC (38) in the Hospital Or Nursing Management industry. This means that A’s stock grew similarly to ALC’s over the last 12 months.
ALC's Profit vs Risk Rating (91) in the Hospital Or Nursing Management industry is in the same range as A (95) in the Biotechnology industry. This means that ALC’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that A’s stock grew somewhat faster than ALC’s over the last 12 months.
A's Price Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for ALC (48) in the Hospital Or Nursing Management industry. This means that A’s stock grew somewhat faster than ALC’s over the last 12 months.
ALC's P/E Growth Rating (17) in the Hospital Or Nursing Management industry is in the same range as A (47) in the Biotechnology industry. This means that ALC’s stock grew similarly to A’s over the last 12 months.
| A | ALC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 56% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 57% |
| Declines ODDS (%) | 14 days ago 64% | 8 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 40% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.